Penile carcinoma is a rare disease that is associated with substantial morbidity. Advances in cytotoxic chemotherapy have been disappointing in the first-line and salvage settings, but the association with human papillomavirus (HPV) infection and a tumour-site agnostic approach form the basis of ongoing clinical trials evaluating immunotherapy strategies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bleeker, M. C. et al. Penile cancer: epidemiology, pathogenesis and prevention. World J. Urol. 27, 141–150 (2009).
Buonerba, C. et al. Prognostic and predictive factors in patients with advanced penile cancer receiving salvage (2nd or later line) systemic treatment: a retrospective, multi-center study. Front. Pharmacol. 7, 487 (2016).
Miralles-Guri, C. et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J. Clin. Pathol. 62, 870–878 (2009).
Stevanovic, S. et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 33, 1543–1550 (2015).
Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386, 2078–2088 (2015).
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).
Trafalis, D. T. et al. Evidence for efficacy of treatment with the anti-PD-1 Mab nivolumab in radiation and multichemorefractory advanced penile squamous cell carcinoma. J. Immunother. 41, 300–305 (2018).
Ottenhof, S. R. et al. Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status. J. Urol. 197, 690–697 (2017).
Necchi, A. et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int. 121, 348–356 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.M. is a consultant for Bayer, Astellas, AstraZeneca, Seattle Genetics, Exelixis, Nektar, Pfizer, Janssen, and Genentech; and has received research support (institutional) from Bristol Myers Squibb (BMS) and speaker fees from Clinical Care Options and OncLive. G.S. is a consultant for Bayer, Sanofi, Pfizer, Novartis, Eisai, Janssen, Amgen, AstraZeneca, Merck, Genentech, Argos, EMD Serono and Agensys/Astellas; has received research support (institutional) from Bayer, Onyx, Celgene, Boehringer-Ingelheim, Merck, Pfizer, Sanofi, Janssen, AstraZeneca, and BMS; has received speaker fees from Clinical Care Options, Physicians Education Resource (PER), Research to Practice (RTP), and Onclive; and is an author for Uptodate.
Rights and permissions
About this article
Cite this article
McGregor, B., Sonpavde, G. Immunotherapy for advanced penile cancer — rationale and potential. Nat Rev Urol 15, 721–723 (2018). https://doi.org/10.1038/s41585-018-0083-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0083-0
This article is cited by
-
Effective combinatorial immunotherapy for penile squamous cell carcinoma
Nature Communications (2020)
